COR

Business Context and Reporting Period

This summary covers the Form 10-Q filed by AmerisourceBergen Corporation (now Cencora, Inc.) for the quarterly period ended March 31, 2008. The Company is a pharmaceutical services provider offering drug distribution and healthcare solutions. Notable structural changes include the July 2007 spin-off of its PharMerica Long-Term Care business and the October 2007 acquisition of Bellco Health. In January 2008, the Company announced an intention to sell its workers' compensation business (PMSI), but terminated this effort in April 2008 due to insufficient bids.

Key Financial Metrics

Note: Gross profit margins decreased to 3.13% (quarter) and 3.03% (six months) compared to prior year periods, primarily due to the absence of the Long-Term Care segment.

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 8% for the quarter and 6% for the six months ended March 31, 2008, compared to the prior year. This was driven by a 9% increase in the Pharmaceutical Distribution segment, aided by the Bellco acquisition and a shift of business from "bulk deliveries" to "operating revenue" due to a new contract with a major customer.
• Profitability: Net income increased 3% for the quarter but decreased 3% for the six months. The decline in the six-month period was offset by a 15% reduction in weighted average shares outstanding due to aggressive share repurchases, resulting in a 14% increase in diluted EPS.
• Segment Performance: The "Other" segment (now primarily PMSI) saw a 76% revenue decline and a 95% operating income decline for the quarter, largely due to the prior year inclusion of the Long-Term Care business which was spun off in July 2007.
• Interest Expense: Net interest expense increased significantly (90% for the quarter, 95% for six months) due to higher average borrowings and lower interest income from reduced cash investments.

Guidance, Outlook, and Risks

• Revenue Guidance: Management expects total revenue growth for fiscal 2008 to range between 7% and 9%. This includes a 3% contribution from the Bellco acquisition.
• PMSI Outlook: The PMSI segment is expected to see revenue declines in fiscal 2008 due to customer losses and competitive pressures. Operating margins are projected to be 2% to 3%, significantly lower than the prior year.
• Share Repurchases: The Company has $302.4 million remaining under its $1.35 billion repurchase program as of March 31, 2008, and expects to purchase a majority of this amount in the next six months.
• Risks and Contingencies:
  • Legal: The Company paid a $28.1 million judgment in April 2008 related to the Bridge Medical matter. It is also subject to a New York Attorney General subpoena regarding alternate source purchasing.
  • Regulatory: Ongoing risks include changes in Medicare/Medicaid reimbursement rates (specifically for anemia drugs and generic pharmaceuticals) and potential impacts from the Deficit Reduction Act of 2005.
  • Impairment: The Company performed a goodwill impairment test on PMSI in March 2008; fair value exceeded net book value, but continued monitoring is required.

Investor Verification Checklist

• Revenue Mix Shift: Verify the impact of transitioning bulk delivery revenue to operating revenue on future margin calculations and comparability.
• PMSI Performance: Monitor the PMSI segment for further customer losses and the success of cost-reduction initiatives following the termination of the sale process.
• Regulatory Exposure: Assess the potential financial impact of CMS reimbursement policy changes regarding anemia drugs and the implementation of the Deficit Reduction Act.
• Legal Reserves: Review the status of the New York Attorney General investigation and any potential liabilities from the Bergen Brunswig executive litigation.
• Cash Flow Volatility: Note the significant decrease in operating cash flow ($710.8M to $92.3M year-over-year for six months) driven by working capital changes (inventory and receivables buildup).